Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUCELL CORP /DE/
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-04-15 | Direct | 11,933 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 11,933 · Balance 11,933 F1: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 19:59 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 11,933 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001437749-26-012554 · rdgdoc.xml · derivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,933 Underlying: Common Stock · 11,933 shares Expires 2036-04-15 F1 · derivative.exercise_date: The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:05 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Exercise / conversionNon Qualified Stock Options (Right to buy) · Derivative | 3.53 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001213900-25-054188 · marketforms-69921.xml · derivative · entry 3 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,530 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: (2) Original stock option was for 15,000 shares. These shares resulted from a net exercise transaction, with 11,470 shares withheld (credited at $6.29 per share, the closing price of the Common stock on the date of exercise) in payment of the exercise price for 3,530 shares. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:05 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Exercise / conversionNon Qualified Stock Options (Right to buy) · Derivative | 11,470 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001213900-25-054188 · marketforms-69921.xml · derivative · entry 2 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,530 Underlying: Common Stock · 11,470 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: (2) Original stock option was for 15,000 shares. These shares resulted from a net exercise transaction, with 11,470 shares withheld (credited at $6.29 per share, the closing price of the Common stock on the date of exercise) in payment of the exercise price for 3,530 shares. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 17:05 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | Exercise / conversionCommon stock $0.10 per value per share | 3,530 | $4.81 | $16,979.30 |
DisclosureSEC source: 0001213900-25-054188 · marketforms-69921.xml · nonDerivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: (1) Shares acquired in stock option net exercise transaction with the Issuer. Read SEC document |
| April 16, 2025 Filed Apr 14, 2026 19:34 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001437749-26-012230 · rdgdoc.xml · derivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-16 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 12:30 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $3.60 Strike: $3.60 | $36,000.00 |
DisclosureSEC source: 0001213900-24-081209 · marketforms-67040.xml · derivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-20 Read SEC document |
| December 15, 2022 Filed Jan 24, 2023 23:24 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 10,000 | $6.52 Strike: $6.52 | $65,200.00 |
DisclosureSEC source: 0001213900-23-004909 · ownership.xml · derivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-15 Read SEC document |
| June 17, 2021 Filed Jun 25, 2021 12:55 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 10,000 | $10.04 Strike: $10.04 | $100,400.00 |
DisclosureSEC source: 0001213900-21-034084 · ownership.xml · derivative · entry 1 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-06-17 Read SEC document |
| June 29, 2020 Filed Jun 25, 2021 12:55 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantIncentive Stock Options (Right to buy) · Derivative | 15,000 | $4.81 Strike: $4.81 | $72,150.00 |
DisclosureSEC source: 0001213900-21-034084 · ownership.xml · derivative · entry 2 Basse Gloria F · CIK 0001869527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-29 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.